We also present compelling evidence to show that drug-resistant breast cancer cells are able to tolerate high levels of nuclear FOXK2 because FOXK2 is deregulated and fails to be recruited to targets genes, such as FOXO3a. This evidence concerns the gene FOXK2 and breast cancer.